Apollo Hospitals Enterprise Ltd , India's leading integrated healthcare services provider, has announced robust financial results for the second quarter of fiscal year 2026, demonstrating strong growth across its core divisions.

Financial Highlights

For Q2 FY26, Apollo Hospitals reported:

• Consolidated revenue growth of 13% year-over-year (YoY) to Rs. 6,304.00 crore
• Consolidated EBITDA increase of 15% YoY to Rs. 941.00 crore
• Consolidated Profit After Tax (PAT) surge of 26% YoY to Rs. 477.00 crore

The company's performance for the first half of FY26 (H1 FY26) was equally impressive:

• Consolidated revenue growth of 14% YoY to Rs. 12,146.00 crore
• Consolidated EBITDA increase of 20% YoY to Rs. 1,793.00 crore
• Consolidated PAT rise of 33% YoY to Rs. 910.00 crore

Segment-wise Performance

Healthcare Services

The Healthcare Services division reported a 9% YoY revenue growth to Rs. 3,169.00 crore in Q2 FY26. EBITDA for this segment grew by 8% YoY to Rs. 781.00 crore, maintaining a strong margin of 24.6%.

Apollo Health and Lifestyle Limited (AHLL)

AHLL, which includes diagnostics and retail healthcare, saw a 17% YoY revenue growth to Rs. 474.00 crore. EBITDA for this segment increased by 21% YoY to Rs. 50.00 crore.

Apollo HealthCo

Apollo HealthCo, encompassing digital healthcare and omni-channel pharmacy platforms, reported a 17% YoY revenue growth to Rs. 2,661.00 crore. The segment's EBITDA stood at Rs. 110.00 crore, compared to Rs. 52.00 crore in Q2 FY25.

Operational Highlights

• Apollo Hospitals operated 8,050 beds across its network, with an overall occupancy rate of 69%.
• The company added 186 new pharmacy stores, bringing the total to 6,928 stores.
• Apollo 24/7, the digital health platform, achieved a Gross Merchandise Value (GMV) of Rs. 723.00 crore in Q2 FY26, representing a 16% growth over Q2 FY25.

Clinical Excellence

Apollo Hospitals continued to demonstrate its leadership in advanced medical procedures and technologies:

• Performed India's first robotic telesurgery for resectable colorectal cancer at Apollo Proton Cancer Centre, Chennai.
• Conducted Deep Brain Stimulation on a 4-year-old child with dystonic cerebral palsy at Apollo Hospitals, Hyderabad.
• Completed over 6,000 pediatric cardiac surgeries and 10,000 interventional procedures at Apollo Children's Hospitals, Chennai.

Future Outlook

Dr. Prathap C Reddy, Chairman of Apollo Hospitals Enterprise Ltd, expressed confidence in the company's growth trajectory, stating, "With robust capacity addition in progress and ongoing clinical innovations in areas such as precision oncology and robotic surgery, we are more confident than ever in our ability to deliver superior care while creating long-term value for all our stakeholders."

The company continues to focus on technological innovation, including AI-driven diagnostics and personalized treatment pathways, to enhance patient care and operational efficiency.

Apollo Hospitals' strong Q2 FY26 results reflect its resilient business model and leadership position in the Indian healthcare sector. The company's focus on expanding its digital health initiatives, coupled with its core hospital operations, positions it well for sustained growth in the coming quarters.

Apollo Hospitals Enterprise Ltd , one of India's leading healthcare providers, has reported robust financial results for the second quarter of fiscal year 2026, demonstrating strong growth across its diverse healthcare segments.

Financial Highlights

The company's consolidated performance for Q2 FY26 shows significant year-over-year improvements:

Segment-wise Performance

Healthcare Services

The Healthcare Services division, which includes hospitals, reported a 9% year-over-year revenue growth to ₹3,169.00 crore. EBITDA for this segment increased by 8% to ₹781.00 crore, maintaining a strong margin of 24.60%.

Apollo Health and Lifestyle Limited (AHLL)

AHLL, which encompasses diagnostics and retail healthcare, saw a robust 17% year-over-year revenue growth, reaching ₹474.00 crore. EBITDA for this segment grew by 21% to ₹50.00 crore.

Apollo HealthCo

The digital healthcare and omni-channel pharmacy platform reported a 17% year-over-year revenue growth to ₹2,661.00 crore. This segment's EBITDA showed significant improvement, reaching ₹110.00 crore compared to ₹52.00 crore in the same quarter last year.

Operational Highlights

• The company maintained an overall hospital occupancy rate of 69%, slightly lower than the 73% reported in the same period last year.
• Apollo HealthCo expanded its offline pharmacy network, adding 186 new stores during the quarter, bringing the total to 6,928 stores.
• The digital platform Apollo 24/7 reported a GMV (Gross Merchandise Value) of ₹723.00 crore, representing a 16% growth over Q2 FY25.

Strategic Developments

Apollo Hospitals continued to focus on technological advancements and expansion:

• Soft-launched Apollo Athenaa, Asia's first dedicated cancer center for women in Delhi.
• Opened a new multi-specialty tertiary care hospital, Royal Mudhol Apollo Hospitals, in Pune.
• Received approval from the Competition Commission of India for the restructuring plan involving group entities, which is expected to unlock shareholder value.

Management Commentary

Dr. Prathap C Reddy, Chairman of Apollo Hospitals Enterprise Ltd, expressed satisfaction with the quarter's performance, highlighting the company's 42-year legacy in healthcare. He emphasized Apollo's commitment to technological innovation, including AI-driven diagnostics and personalized treatment pathways.

Conclusion

Apollo Hospitals' Q2 FY26 results demonstrate the company's strong position in the Indian healthcare sector, with growth across all major segments. The focus on technological advancements and expansion of both physical and digital healthcare services positions Apollo well for continued growth in the evolving healthcare landscape.

Investors and stakeholders may view these results positively, considering the robust financial performance and strategic initiatives undertaken by the company. However, it's important to note that future performance may be subject to various factors including market conditions and regulatory environments.